Navigation Links
Enoxaparin To Become The Standard Treatment During Procedures For Blocked Arteries

In a new study by researchers from the University of Kentucky being claims to one day change the standard treatment for preventing blood clots during procedures so// as to open up blocked arteries that feed the heart.

According to Dr. Steven Steinhubl, the co-chairman and senior author of the study that is to appear in the latest issue of the New England Journal of Medicine, has claimed that the drug ‘Enoxaparin’, that has been studied has the potential to become a standard treatment during the procedures of stent and angioplasty. Explaining that the current standard of care is to give patients unfractionated heparin, he however cautioned that more research is necessary to come to a definitive conclusion.

Steinhubl, an interventional cardiologist and researcher at UK's Linda and Jack Gill Heart Institute, said that while elective stent and angioplasty procedures to clear blocked arteries are generally safe, a small percentage of patients will experience significant bleeding due to the procedure that can increase the cost and duration of the hospital stay and, in rare instances, even cause death.

In the study, researchers examined Enoxaparin to determine if it is a safe and effective anti-clotting drug, carrying less risk for bleeding following the procedure than unfractionated heparin.

The study found that major bleeding was cut by more than half in patients receiving Enoxaparin. It also showed that doctors were much more likely to achieve the targeted level of blood thinning for their patients with Enoxaparin compared with unfractionated heparin.

"Bleeding following a stent placement or angioplasty is an event that is not only dangerous for patients, but also carries a financial burden for the health care industry as a whole," Steinhubl said. "Millions of these procedures are successfully performed at hospitals across the United States each year. It is important that we make what has become a relatively sa fe procedure even safer by finding a drug that will effectively prevent blood clots and not put patients at risk for unnecessary bleeding. This study, which was designed to test the safety of Enoxaparin, is one of the first steps we as cardiologists are taking to reach that goal."

Source-Eurekalert
VI
'"/>




Related medicine news :

1. Overweight children Dont Necessarily Become overweight adults
2. Girls Who Undergo Genital Mutilation Can Become Infertile
3. Genetic Tests Could Become As Affordable As Blood Tests
4. Obesity Among Children May Become a Major Problem
5. Manned Mars Mission May Become A Reality
6. Malaria Detecting Watch May Become A Health Hazard
7. Children Of Alcoholics Tend to Become Drug Abusers In Adulthood
8. Kerala To Become Testing Center For US Bound Nurses
9. Himachal Pradesh Fails To Become Health Tourism Center
10. Cancer Treatment To Become Less Expensive
11. India Can Become Major HIV Drugs Producer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... Illustrate, Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time ... Rights (OCR) HIPAA audit and properly satisfy the law. , Thanks to the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and social campaign, “Humans With Vaginas.” The goal is to ignite conversation via ... non-toxic personal care products. The brand has declared September “Humans with Vaginas” month, ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment ... 8, and Monday, September 11, off work and rolled up their sleeves to help ... to local homes to start the process of rebuilding. , CORDA founder Bonner C. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology: